Predictive value of pre-procedural autoantibodies against M2-muscarinic acetylcholine receptor for recurrence of atrial fibrillation one year after radiofrequency catheter ablation

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Zou, Changhong ^a   Zhang, Zhiyong ^a   Zhao, Wenmin ^a   Li, Guang ^a   Ma, Guiling ^a   Yang, Xinchun ^a   Zhang, Jianjun ^a   Zhang, Lin ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Atrial fibrillation; Autoantibody; Muscarinic 2 acetylcholine receptor; Radiofrequency catheter ablation; Recurrence

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; AUTOANTIBODY; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; MUSCARINIC M2 RECEPTOR;

AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CATHETER ABLATION; CHINA; CONTROLLED STUDY; DISEASE DURATION; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROSPECTIVE STUDY; RECURRENT DISEASE; RISK ASSESSMENT; SINUS RHYTHM; UNIVARIATE ANALYSIS;

AGED; ATRIAL FIBRILLATION; AUTOANTIBODIES; CATHETER ABLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECEPTOR, MUSCARINIC M2; RECURRENCE; TREATMENT OUTCOME;

EID: 84871913117     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-7     Document Type: Article

References (17)

1. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Prior SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, et al. ACC/AHA/ESC 2006 Guideliines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. Circulation 2006, 114:e257-e354.
2. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, AI-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Helda M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH, . European Heart Rhythm Association European Association for Cardio-Thoracic Surgery Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010, 31:2369-2429. European Heart Rhythm Association European Association for Cardio-Thoracic Surgery.
3. Baba A, Fu M. Autoantibodies in atrial fibrillation: Actor, biomarker or bystander?. Autoimmunity 2008, 41:470-472. 10.1080/08916930802031504, 18781473.
4. Fu M, Magnusson Y, Bergh CH, Liljeqvist JA, Waagstein F, Hjalmarson A, Hoebeke J. Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy. J Chin Invest 1993, 91:1964-1968.
5. Sterin-Borda L, Gorelik G, Borda ES. Chagasic IgG bingding with cardiac muscarinic cholinergic receptors modifies cholinergic-mediated cellular transmembrane signals. Clinical Immunol Immunopathol 1991, 61:387-397.
6. Baba A, Yoshikawa T, Fukuda Y, Sugiyama T, Shimada M, Akaishi M, Tsuchimoto K, Ogawas S, Fu M. Autoantibodies against M2-muscarinic acetylcholine receptors: new upstream targets in atrial fibrillation in patients with dilated cardiomyopathy. Eur Heart J 2004, 25:1108-1115. 10.1016/j.ehj.2004.05.012, 15231368.
7. Chiale PA, Ferrari I, Mahler E, Vallazza MA, Elizari MV, Rosenbaum MB, Levin MJ. Differential profile and biochemical effects of antiautonomic membrane receptor antibodies in ventricular arrhythmias and sinus node dysfunction. Circulation 2001, 103:1765-1771. 10.1161/01.CIR.103.13.1765, 11282908.
8. Stavrakis S, Yu X, Patterson E, Huang S, Hamlett SR, Chalmers L, Pappy R, Cunningham MW, Morshed SA, Davies TF, Lazzara R, Kem DC. Activating autoantibodies to the beta-1 adrenergic and M2 muscarinic receptors facilitate atrial fibrillation in patients with Graves' hyperthyroidism. J Am Coll Cardiol 2009, 54:1309-1316. 10.1016/j.jacc.2009.07.015, 2801559, 19778674.
9. Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJ, Damiano RJ, Davies DW, Haines DE, Haissaguerre M, Iesaka Y, Jackman W, Jais P, Kottkamp H, Kuck KH, Lindsay BD, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Natale A, Pappone C, Prystowsky E, Raviele A, Ruskin JN, Shemin RJ. HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Personnel, Policy, Procedures and Follow-up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS). Europace 2007, 9:335-379. 10.1093/europace/eum120, 17599941.
10. Lellouche N, Berthier R, Mekontso-Dessap A, Braconnier F, Monin JL, Duval AM, Dubois-Randé JL, Guéret P, Garot J. Usefulness of Plasma B-Type Natriuretic Peptide in Predicting Recurrence of Atrial Fibrillation One Year After External Cardioversion. Am J Cardiol 2005, 95:1380-1382. 10.1016/j.amjcard.2005.01.090, 15904651.
11. Berruezo A, Tamborero D, Mont L, Benito B, Tolosana JM, Sitges M, Vidal B, Arriagada G, Méndez F, Matiello M, Molina I, Brugada J. Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. Eur Heart J 2007, 28:836-841. 10.1093/eurheartj/ehm027, 17395676.
12. Kovoor P, Wickman K, Maguire CT, Pu W, Gehrmann J, Berul CI, Clapham DE. Evaluation of the role of I (KACh) in atrial fibrillation using a mouse knockout model. J Am Coll Cardiol 2001, 37:2136-2143. 10.1016/S0735-1097(01)01304-3, 11419900.
13. Hong CM, Zheng QS, Liu XT. Anti-M2 muscarinic acetylcholine receptor autoantibodies: new therapeutic targets in atrial fibrillation. Bioscience Hypotheses 2008, 1:162-164.
14. Boldt A, Wetzel U, Lauschke J, Weigl J, Gummert J, Hindricks G, Kottkamp H, Dhein S. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 2004, 90:400-405. 10.1136/hrt.2003.015347, 1768173, 15020515.
15. Chen YJ, Chen SA, Tai CT, Wen ZC, Feng AN, Ding YA, Chang MS. Role of atrial electrophysiology and autonomic nervous system in patients with superventricular tachycardia and paroxysmal atrial fibrillation. J Am Coll Cardiol 1998, 32:732-737. 10.1016/S0735-1097(98)00305-2, 9741520.
16. Hong CM, Zheng QS, Liu XT, Shang FJ, Wang HT, Jiang WR. Effects of Autoantibodies against M2 muscarinic acetylcholine receptors on rabbit atria in vivo. Cardiology 2009, 112:180-187. 10.1159/000149152, 18679026.
17. Hwang HJ, Son JW, Nam BH, Joung B, Lee B, Kim JB, Lee MH, Jang Y, Chung N, Shim WH, Cho SY, Kim SS. Incremental predictive value of pre-procedural N-terminal pro-B-type natriuretic peptide for short-term recurrence in atrial fibrillation ablation. Clin Res Cardiol 2009, 98:213-218. 10.1007/s00392-009-0744-3, 19229464.